Stuttgart
22.06.26 | 17:14
1,078 Euro
-0,37 % -0,004
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:12 | Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million | 287 | Business Wire | The transaction reflects the commitment of key shareholders, such as Cemag Invest and Didier Laurens, Chairman and CEO, joined by Europe Offering and L1 Capital. Immediate funding of €1.4... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 01.06. | Advicenne Granted Reimbursement for Likozam in France and Sees Thereby Its Debt Reduced by Nearly €6 Million | 246 | Business Wire | Likozam will be reimbursed to patients starting June 12, 2026 Official reimbursement ends the "Early Access" clawback The price obtained offsets the discounts owed under the early... ► Artikel lesen | |
| 21.05. | Advicenne Announces Changes to Its Governance Following Its Annual General Meeting on May 21, 2026 | 389 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 -ALDVI), a pharmaceutical company specializing in the development and marketing of innovativetreatments for people suffering from... ► Artikel lesen | |
| 05.05. | Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway | 524 | Business Wire | A proactive initiative to restructure the Company's debt A protective framework that allows for the continuation of commercial, clinical, and regulatory activities, as well as discussions... ► Artikel lesen | |
| 24.04. | ADVICENNE: Advicenne 2025 Universal Registration Document made available | 1 | Euronext | ||
| 24.04. | Advicenne 2025 Universal Registration Document Made Available | 369 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 26.03. | Advicenne Reports Its 2025 Annual Financial Results | 3.230 | Business Wire | Product sales up 18.7% to €5.8 million
European end-market sales of Sibnayal rose by more than 71% to nearly €11 million
Royalties doubled to over €1.1 million
Cash position... ► Artikel lesen | |
| 02.02. | Advicenne: Official Reimbursement of Sibnayal for the Treatment of dRTA in France | 1.428 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 27.01. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in UAE | 435 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 22.01. | Advicenne: 2025 Full Year Sales | 520 | Business Wire | 2025 sales totaled €5.73m, up 18.4%
Sibnayal sales rose 36.6% to €3.01m
2025 Royalties are estimated at €1m, double the amount for 2024
End-markets estimated sales of Sibnayal... ► Artikel lesen | |
| 20.01. | Advicenne: 2026 Financial Calendar | 456 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 19.01. | Advicenne's Sibnayal NDA For DRTA Tratement Accepted For Review By FDA | 2 | RTTNews | ||
| 19.01. | Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal in the United States for the Treatment of dRTA | 357 | Business Wire | The US regulatory agency has set the target date for the final approval decision, known as the PDUFA date, as of September 3rd, 2026.
Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746... ► Artikel lesen | |
| 12.01. | Advicenne Has Successfully Renewed the Marketing Authorization of Sibnayal in European Union | 350 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 535 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 19.09.25 | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 600 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08.25 | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 436 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07.25 | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 624 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07.25 | Advicenne Reports its H1 2025 Sales | 537 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07.25 | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 1.022 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,960 | -0,95 % | Pfizer-Finanzchef geht im August | NEW YORK (dpa-AFX) - Pfizer steht vor einem Wechsel im Finanzressort. Wie der US-Pharmakonzern am Donnerstag in New York mitteilte, wird Finanzvorstand Dave Denton sein Amt zum 15. August niederlegen... ► Artikel lesen | |
| ABBVIE | 201,70 | +5,91 % | AbbVie-Aktie: Neue Chancen nach Mega-Blockbuster Humira | Der Pharmakonzern AbbVie hält Kurs auf weiteres Wachstum und treibt die Expansion seiner wichtigsten Produkte konsequent voran. Besonders die Blockbuster Skyrizi und Rinvoq gewinnen zunehmend an Bedeutung... ► Artikel lesen | |
| HAEMATO | 13,000 | 0,00 % | M1 Kliniken schließt Verkauf von Haemato Pharm ab | Die M1 Kliniken AG hat den Verkauf der Haemato Pharm GmbH über ihre Mehrheitsbeteiligung Haemato AG an die Phoenix Group mit Wirkung zum Ablauf des 31. Januar 2026 abgeschlossen. Sämtliche Vollzugsbedingungen... ► Artikel lesen | |
| HALEON | 3,873 | +0,34 % | Haleon kauft über 14 Millionen Aktien zur Einziehung zurück | ||
| ACHIEVE LIFE SCIENCES | 4,580 | +7,51 % | Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA | CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 220,00 | -8,33 % | Ligand prices proposed $550M convertible senior notes offering | ||
| ROYALTY PHARMA | 45,380 | +0,50 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| EISAI | 21,340 | +0,33 % | Eisai Announces Strategic Investment Supported by the UK Government's LSIMF | Strategic investment in the Hatfield manufacturing site in the UK to help establish in-house capabilities for medicines requiring cold-chain managementTOKYO, June 17, 2026 - (JCN Newswire) - Eisai Co.... ► Artikel lesen | |
| TG THERAPEUTICS | 47,700 | +2,36 % | TG Therapeutics, Inc.: TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial | 82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed... ► Artikel lesen | |
| DR REDDYS | 12,000 | +5,26 % | Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO in Select International Markets | Agreement expands access to XACDURO for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,033 | 0,00 % | BetterLife Pharma Inc.: BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing | Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD... ► Artikel lesen | |
| ENTOURAGE HEALTH | - | - | Ontario Securities Commission: OSC bans WeedMD ex Carr, again | ||
| WAVE LIFE SCIENCES | 5,450 | +3,81 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing | Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with... ► Artikel lesen | |
| KYOWA KIRIN | 14,000 | +0,72 % | Kura Oncology, Inc.: Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML | - 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial - - 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML... ► Artikel lesen | |
| IGC PHARMA | 0,248 | +3,33 % | IGC Pharma, Inc.: IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis | Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire /... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.